Ajanta Pharma Limited — Q1 FY25
Ajanta Pharma delivered a strong Q1 FY25 with revenue of INR 1,145 crore (+12% YoY) and EBITDA of INR 330 crore (+22% YoY), driven by branded generics growth of 17%.
bullish
high
Financial stats pending filing verification
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
FY24 EBITDA margin guidance revised to 27% ±1%
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
India business to grow low double digits in FY24
India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Asia branded to grow low teens in FY24
Asia branded business expected to grow low double digits for full year FY24.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Africa branded to grow mid to high single digits in FY24
Africa branded business expected to grow mid to high single digits for full year FY24.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1